BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

BioMarin Pharmaceutical Inc. announced on August 31 that it had entered into binding agreements with Ascendis Pharma A/S to resolve a global patent dispute concerning Ascendis’s achondroplasia treatment Yuviwel. The settlement addressed litigation pending across multiple jurisdictions, including a Section 337 investigation by the US International Trade Commission that BioMarin agreed to withdraw. Ascendis confirmed the arrangement the following day, characterizing it as a binding term she